Similar articles

• Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.

  Pescovitz MD, Henson S, Bodziak K, Book BK, Gonin J, Jindal RM, Leapman SB, Milgrom ML, Filo RS. Pescovitz MD, et al. Transplant Proc. 1996 Aug;28(4):2165-8. Transplant Proc. 1996. PMID: 8769189 Clinical Trial. No abstract available.
• Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.

  Schiavelli R, Sgrosso JL, Sabbatiello R, Castro C, Ahualli L, Pattin M, Vazquez MC. Schiavelli R, et al. Transplant Proc. 1996 Dec;28(6):3343-4. Transplant Proc. 1996. PMID: 8962299 No abstract available.
• The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.

  Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Chang C, Choc M, et al. Kahan BD, et al. Transplant Proc. 1994 Oct;26(5):2940-3. Transplant Proc. 1994. PMID: 7940928 Clinical Trial. No abstract available.
• Pharmacokinetics of oral cyclosporine A in stable kidney transplant recipients: a critical review.

  Foradori AC, Martínez L, Elberg A, Vacarezza A, Loveluck A, Pinto C. Foradori AC, et al. Transplant Proc. 1995 Apr;27(2):1815-6. Transplant Proc. 1995. PMID: 7725516 Review. No abstract available.
• Sandimmun neoral pharmacokinetics: impact of the new oral formulation.

  Holt DW, Mueller EA, Kovarik JM, van Bree JB, Richard F, Kutz K. Holt DW, et al. Transplant Proc. 1995 Feb;27(1):1434-7. Transplant Proc. 1995. PMID: 7878935 Review. No abstract available.